Skip to main content

Advertisement

Log in

Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphotic leukemia

  • Case report
  • Published:
Hematology and Cell Therapy

Abstract

Fludarabine phosphate (FDR) has demonstrated a remarkable clinical activity in chronic lymphocytic leukemia (CLL). Myelosuppression is the main toxicity although autoimmune hemolytic anemia (AIHA) is frequently reported. The pathogenesis of AIHA is still unknown however the role of T-cell immunosuppression is suspected. One case of thrombopenia after FDR has been described in a patient with a previous history of an autoimmune thrombocytopenia. We here report a 73-year-old man with a B-CLL and no previous autoimmune disorder who received six courses of fludarabine phosphate and developed afterwards an autoimmune thrombocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bay, J.O., Fouassier, M., Béal, D. et al. Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphotic leukemia. Hematol Cell Ther 39, 209–212 (1997). https://doi.org/10.1007/s00282-997-0209-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00282-997-0209-y

Key words

Navigation